Vimarsana
Biggest News Aggregation in the World

Page 24 - Bio Developments News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bio Developments. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bio Developments Today - Breaking & Trending Today

Why Adial is developing a pill for alcohol addiciton: 'Abstinence is not the only road to recovery' - Vimarsana News

Why Adial is developing a pill for alcohol addiciton: 'Abstinence is not the only road to recovery'

We sat down with Cary Claiborne, CEO and president of Adial Pharma, to discuss the challenges of treating alcohol abuse and company's solution – a serotonin-3 receptor antagonist that could affect neurotransmitters like dopamine and modulate the behavioural effects of alcohol.

Angle unveils new cancer diagnostic at San Antonio Breast Cancer Symposium - Vimarsana News

Angle unveils new cancer diagnostic at San Antonio Breast Cancer Symposium

Liquid biopsy company Angle has announced the launch of its Portrait+ CTC staining kit at the San Antonio Breast Cancer Symposium (SABCS).

Pfizer axes new weight loss pill after patients experience serious side effects - Vimarsana News

Pfizer axes new weight loss pill after patients experience serious side effects

Pfizer is discontinuing danuglipron, its twice-daily weight loss pill, after more than half of patients in a clinical trial stopped taking it.

GSK RSV vaccine revenue to reach $1.26 billion in first year - Vimarsana News

GSK RSV vaccine revenue to reach $1.26 billion in first year

GSK CEO Emma Walmsley has told Reuters that the company’s respiratory syncytial virus (RSV) vaccine is expected to make over $1.26 billion in its first year on the market.

Lumen Bioscience bags $5.5 million to develop needle-free vaccines - Vimarsana News

Lumen Bioscience bags $5.5 million to develop needle-free vaccines

Lumen Bioscience, a clinical-stage biopharma company developing biologic drugs for highly prevalent disease, has received $5.5 million in new funding from the U.S. Department of Defense, to develop technologies for needle-free vaccines.